Brief: Recursion Pharmaceuticals Q2 Net Income USD -97.54 Million
08/08/2024 12:31
Aug 08 (Reuters) - Recursion Pharmaceuticals Q2 pretax profit USD -98.063 million. * Q2 operating revenue USD 14.404 million * Q2 operating income USD -100.543 million
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million